Cash/Burn From Filing For Period: 

Q3 '19

ESPR

Esperion

ESPERION is passionately committed to developing and commercializing oral, LDL-C lowering therapies for patients with hypercholesterolemia.

Cash

243.9M

Burn Rate

$68.4M

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Bempedoic acid Hyperlipidemia

LDL-C is not adequately controlled with low- and moderate-dose statins

PDUFA

2/21/2020

Bempedoic Acid/ Ezetimibe

Hypercholesterolemia

PDUFA

2/26/2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon